- Home
- USPH vs VRDN Comparison
USPH vs VRDN Comparison
Compare USPH & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USPH
- VRDN
- Stock Information
- Founded
- USPH 1990
- VRDN 2006
- Country
- USPH United States
- VRDN United States
- Employees
- USPH N/A
- VRDN N/A
- Industry
- USPH Medical/Nursing Services
- VRDN Medical Specialities
- Sector
- USPH Health Care
- VRDN Health Care
- Exchange
- USPH Nasdaq
- VRDN Nasdaq
- Market Cap
- USPH 1.1B
- VRDN 1.0B
- IPO Year
- USPH 1992
- VRDN N/A
- Fundamental
- Price
- USPH $75.04
- VRDN $13.92
- Analyst Decision
- USPH Strong Buy
- VRDN Strong Buy
- Analyst Count
- USPH 4
- VRDN 12
- Target Price
- USPH $109.00
- VRDN $38.50
- AVG Volume (30 Days)
- USPH 108.2K
- VRDN 838.2K
- Earning Date
- USPH 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- USPH 2.40%
- VRDN N/A
- EPS Growth
- USPH 81.25
- VRDN N/A
- EPS
- USPH 2.17
- VRDN N/A
- Revenue
- USPH $692,325,000.00
- VRDN $302,000.00
- Revenue This Year
- USPH $16.83
- VRDN N/A
- Revenue Next Year
- USPH $6.06
- VRDN $21,976.14
- P/E Ratio
- USPH $34.49
- VRDN N/A
- Revenue Growth
- USPH 14.30
- VRDN 4.86
- 52 Week Low
- USPH $62.77
- VRDN $9.90
- 52 Week High
- USPH $102.89
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- USPH 50.71
- VRDN 55.94
- Support Level
- USPH $73.20
- VRDN $13.37
- Resistance Level
- USPH $77.14
- VRDN $14.18
- Average True Range (ATR)
- USPH 2.17
- VRDN 0.67
- MACD
- USPH -0.29
- VRDN 0.14
- Stochastic Oscillator
- USPH 23.03
- VRDN 85.65
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).